Showing 20 of 84 recruiting trials for “primary-plasmacytoma-of-the-bone”
Universal CAR-T Cell Therapy for MM
Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell Transplant
👨⚕️ Dilan A Patel, M.D., Washington University School of Medicine📍 1 site📅 Started Apr 2025View details ↗
Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma
RecruitingNCT06644625 ↗
CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
👨⚕️ Manisha Bhutani, MD, Atrium Health Wake Forest Baptist Comprehensive Cancer Center📍 1 site📅 Started Mar 2025View details ↗
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
👨⚕️ Barry A Paul, MD, Wake Forest University Health Sciences📍 2 sites📅 Started Feb 2025View details ↗
SBRT Plus Lenalidomide for Solitary Plasmacytoma: Phase II Trial
🏥 Second Affiliated Hospital, School of Medicine, Zhejiang University📍 1 site📅 Started Feb 2025View details ↗
A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
👨⚕️ David Avigan, MD, Beth Israel Deaconess Medical Center📍 2 sites📅 Started Jan 2025View details ↗
RecruitingNCT06846905 ↗
Cost-utility Analysis of Ambulatory Dose Escalation of Bispecific Antibodies in Multiple Myeloma.
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
👨⚕️ Ricardo D Parrondo, Dana-Farber - Harvard Cancer Center LAO📍 14 sites📅 Started Dec 2024View details ↗
VitD3 Supplementation in Patients With Multiple Myeloma
👨⚕️ Amany Keruakous, MD, Georgia Cancer Center at Augusta University📍 1 site📅 Started Dec 2024View details ↗
Risk Stratification and MRD-driven Maintenance for MM After ASCT
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma
👨⚕️ Armin Ghobadi, M.D., Washington University School of Medicine📍 1 site📅 Started Aug 2024View details ↗
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients
👨⚕️ Ying Lu, The Affiliated People's Hospital of Ningbo University📍 16 sites📅 Started Aug 2024View details ↗
RecruitingNCT06338150 ↗
Precision Medicine Study
👨⚕️ Cesar Rodriguez Valdes, MD, PhD, Icahn School of Medicine at Mount Sinai📍 1 site📅 Started Jul 2024View details ↗
Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab)
Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients
Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →